Home > Publications Database > Impact of atrial fibrillation burden on cognitive function after left atrial ablation - Results of the MACPAF study. > print

001     144990
005     20250717155812.0
024 7 _ |a 10.1016/j.jocn.2019.12.030
|2 doi
024 7 _ |a pmid:31992513
|2 pmid
024 7 _ |a 0967-5868
|2 ISSN
024 7 _ |a 1532-2653
|2 ISSN
024 7 _ |a altmetric:74720777
|2 altmetric
037 _ _ |a DZNE-2020-00354
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Herm, Juliane
|b 0
245 _ _ |a Impact of atrial fibrillation burden on cognitive function after left atrial ablation - Results of the MACPAF study.
260 _ _ |a Burlington, Mass.
|c 2020
|b Harcourt
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2020-03-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1752760475_26599
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Atrial fibrillation (AF) is associated with cognitive decline and dementia irrespective of AF-related ischemic stroke. We investigated whether AF burden after ablation in patients with symptomatic paroxysmal AF has an impact on cognitive function. After enrolment to the prospective MACPAF study, study patients received an insertable loop recorder (ILR) and underwent serial neurological/cognitive assessment. To compare cognitive function, the delta of baseline and six months test results (Δpre/post) and a score to assess overall cognitive performance were computed. Thirty patients (median age 65 years (IQR 57-69), 40% female) were divided into groups according to median AF burden (<0.5% vs. ≥0.5%) after ablation. Overall cognitive performance did not differ in patients with an AF burden < 0.5% (median 120% [IQR 100-150]) vs. ≥0.5% (median 120% [IQR 100-160]) within six months after ablation (p = 0.74). Comparing Δpre/post, patients with an AF burden ≥ 0.5% showed significantly better results in the digit-span backwards test (median + 1 [IQR 0 - +2 points]) compared to patients with an AF burden < 0.5% (median 0 [IQR -1-+1]) six months after ablation (p = 0.03). In patients with an AF burden < 0.5%, there was a statistical trend towards better results in the RAVLT test (median + 3 [IQR 0-+4]; p = 0.08) and the ROC test (median + 3 [IQR -1-+5; p = 0.07) compared to patients with an AF burden ≥ 0.5% (median -1 [IQR -3-+2] words and median -1 [IQR -5-+2] points, respectively). Therefore, AF burden had no significant impact on cognitive performance within six months after ablation. Clinical Trial Registration: clinicaltrials.gov NCT01061931.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
542 _ _ |i 2020-03-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Atrial Fibrillation: complications
|2 MeSH
650 _ 2 |a Atrial Fibrillation: physiopathology
|2 MeSH
650 _ 2 |a Atrial Fibrillation: surgery
|2 MeSH
650 _ 2 |a Catheter Ablation: methods
|2 MeSH
650 _ 2 |a Cognition
|2 MeSH
650 _ 2 |a Cognition Disorders: epidemiology
|2 MeSH
650 _ 2 |a Cognition Disorders: etiology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
700 1 _ |a Schirdewan, Alexander
|b 1
700 1 _ |a Koch, Lydia
|b 2
700 1 _ |a Wutzler, Alexander
|b 3
700 1 _ |a Fiebach, Jochen B
|b 4
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 5
|u dzne
700 1 _ |a Kopp, Ute A
|b 6
700 1 _ |a Haeusler, Karl Georg
|0 P:(DE-HGF)0
|b 7
|e Corresponding author
773 1 8 |a 10.1016/j.jocn.2019.12.030
|b : Elsevier BV, 2020-03-01
|p 168-172
|3 journal-article
|2 Crossref
|t Journal of Clinical Neuroscience
|v 73
|y 2020
|x 0967-5868
773 _ _ |a 10.1016/j.jocn.2019.12.030
|g Vol. 73, p. 168 - 172
|0 PERI:(DE-600)2009190-4
|p 168-172
|t Journal of clinical neuroscience
|v 73
|y 2020
|x 0967-5868
856 4 _ |u https://pub.dzne.de/record/144990/files/DZNE-2020-00354_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/144990/files/DZNE-2020-00354_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:144990
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-10
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN NEUROSCI : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-17
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21